Early IFN type I response: Larning from microbial evasion strategies

Seminars in Immunology

Volumn 27, Issue 2, 2015, Pages 85-101

  Coccia, Eliana M ^a   Battistini, Angela ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Bacteria; Evasion mechanism; IFN stimulated genes; Interferon; Signaling; Virus

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PROTEIN KINASE R; UBIQUITIN;

ADAPTIVE IMMUNITY; BACTERIUM; BIOSENSOR; CHRONIC DISEASE; HOST RESISTANCE; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; INNATE IMMUNITY; MICROBIAL IMMUNITY; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; VIRUS; VIRUS REPLICATION; BACTERIAL INFECTION; CLASSIFICATION; IMMUNOLOGY; MICROBIOLOGY; VIROLOGY; VIRUS INFECTION;

BACTERIA; BACTERIAL INFECTIONS; IMMUNE EVASION; INTERFERON TYPE I; SIGNAL TRANSDUCTION; VIRUS DISEASES; VIRUSES;

EID: 84931570382     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.03.005     Document Type: Review

References (260)

1. Wu J., Chen Z.J. Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 2014, 32:461-488.
2. Sancho D., Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu. Rev. Immunol. 2012, 30:491-529.
3. Paludan S.R., Bowie A.G. Immune sensing of DNA. Immunity 2013, 38:870-880.
4. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
5. Barbe F., Douglas T., Saleh M. Advances in Nod-like receptors (NLR) biology. Cytokine Growth Factor Rev. 2014.
6. Unterholzner L. The interferon response to intracellular DNA: why so many receptors?. Immunobiology 2013, 218:1312-1321.
7. Mansur D.S., Smith G.L., Ferguson B.J. Intracellular sensing of viral DNA by the innate immune system. Microbes Infect. 2014.
8. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
9. Honda K., Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 2006, 6:644-658.
10. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014, 14:36-49.
11. Schneider W.M., Chevillotte M.D., Rice C.M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 2014, 32:513-545.
12. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
13. Reid E., Charleston B. Type I and III interferon production in response to RNA viruses. J. Interferon Cytokine Res. 2014, 34:649-658.
14. Samarajiwa S.A., Forster S., Auchettl K., Hertzog P.J. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res. 2009, 37:D852-D857.
15. Stark G.R., Darnell J.E. The JAK-STAT pathway at twenty. Immunity 2012, 36:503-514.
16. Stetson D.B., Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381.
17. Coccia E.M. IFN regulation and functions in myeloid dendritic cells. Cytokine Growth Factor Rev. 2008, 19:21-32.
18. Carrero J.A. Confounding roles for type I interferons during bacterial and viral pathogenesis. Int. Immunol. 2013, 25:663-669.
19. Reddick L.E., Alto N.M. Bacteria fighting back: how pathogens target and subvert the host innate immune system. Mol. Cell 2014, 54:321-328.
20. Finlay B.B., McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 2006, 124:767-782.
21. Baxt L.A., Garza-Mayers A.C., Goldberg M.B. Bacterial subversion of host innate immune pathways. Science 2013, 340:697-701.
22. Weber F., Kochs G., Haller O. Inverse interference: how viruses fight the interferon system. Viral Immunol. 2004, 17:498-515.
23. Versteeg G.A., Garcia-Sastre A. Viral tricks to grid-lock the type I interferon system. Curr. Opin. Microbiol. 2010, 13:508-516.
24. Bowie A.G., Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 2008, 8:911-922.
25. Orzalli M.H., Knipe D.M. Cellular sensing of viral DNA and viral evasion mechanisms. Annu. Rev. Microbiol. 2014, 68:477-492.
26. Rosadini C.V., Kagan J.C. Microbial strategies for antagonizing Toll-like-receptor signal transduction. Curr. Opin. Immunol. 2015, 32C:61-70.
27. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
28. Iwasaki A. A virological view of innate immune recognition. Annu. Rev. Microbiol. 2012, 66:177-196.
29. Pandey S., Kawai T., Akira S. Microbial sensing by toll-like receptors and intracellular nucleic acid sensors. Cold Spring Harb. Perspect. Biol. 2015, 7a016246.
30. Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 2008, 205:1601-1610.
31. Pichlmair A., Schulz O., Tan C.P., Naslund T.I., Liljestrom P., Weber F., et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314:997-1001.
32. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
33. Abdullah Z., Schlee M., Roth S., Mraheil M.A., Barchet W., Bottcher J., et al. RIG-I detects infection with live Listeria by sensing secreted bacterial nucleic acids. EMBO J. 2012, 31:4153-4164.
34. Li X.D., Chiu Y.H., Ismail A.S., Behrendt C.L., Wight-Carter M., Hooper L.V., et al. Mitochondrial antiviral signaling protein (MAVS) monitors commensal bacteria and induces an immune response that prevents experimental colitis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:17390-17395.
35. Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
36. Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455:674-678.
37. Zhong B., Yang Y., Li S., Wang Y.Y., Li Y., Diao F., et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 2008, 29:538-550.
38. Ran Y., Shu H.B., Wang Y.Y. MITA/STING: a central and multifaceted mediator in innate immune response. Cytokine Growth Factor Rev. 2014, 25:631-639.
39. Dabo S., Meurs E.F. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 2012, 4:2598-2635.
40. Diamond M.S. IFIT1: a dual sensor and effector molecule that detects non-2'-O methylated viral RNA and inhibits its translation. Cytokine Growth Factor Rev. 2014.
41. Philpott D.J., Sorbara M.T., Robertson S.J., Croitoru K., Girardin S.E. NOD proteins: regulators of inflammation in health and disease. Nat. Rev. Immunol. 2014, 14:9-23.
42. Vanaja S.K., Rathinam V.A., Fitzgerald K.A. Mechanisms of inflammasome activation: recent advances and novel insights. Trends Cell Biol. 2015.
43. Hui D.S., Wong G.W. Advancements in the battle against severe acute respiratory syndrome. Expert Opin. Pharmacother. 2004, 5:1687-1693.
44. de Groot R.J., Baker S.C., Baric R.S., Brown C.S., Drosten C., Enjuanes L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J. Virol. 2013, 87:7790-7792.
45. Coleman C.M., Frieman M.B. Coronaviruses: important emerging human pathogens. J. Virol. 2014, 88:5209-5212.
46. Hilgenfeld R., Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Res. 2013, 100:286-295.
47. Hui D.S., Memish Z.A., Zumla A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr. Opin. Pulm. Med. 2014, 20:233-241.
48. Zielecki F., Weber M., Eickmann M., Spiegelberg L., Zaki A.M., Matrosovich M., et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J. Virol. 2013, 87:5300-5304.
49. Kindler E., Jonsdottir H.R., Muth D., Hamming O.J., Hartmann R., Rodriguez R., et al. Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio 2013, 4:e00611-e00612.
50. Kindler E., Thiel V. To sense or not to sense viral RNA - essentials of coronavirus innate immune evasion. Curr. Opin. Microbiol. 2014, 20:69-75.
51. Totura A.L., Baric R.S. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr. Opin. Virol. 2012, 2:264-275.
52. Zust R., Cervantes-Barragan L., Habjan M., Maier R., Neuman B.W., Ziebuhr J., et al. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 2011, 12:137-143.
53. Menachery V.D., Debbink K., Baric R.S. Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments. Virus Res. 2014.
54. Daffis S., Szretter K.J., Schriewer J., Li J., Youn S., Errett J., et al. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 2010, 468:452-456.
55. Menachery V.D., Yount B.L., Josset L., Gralinski L.E., Scobey T., Agnihothram S., et al. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2'-O-methyltransferase activity. J. Virol. 2014, 88:4251-4264.
56. Bouvet M., Imbert I., Subissi L., Gluais L., Canard B., Decroly E. RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:9372-9377.
57. Shi X., Wang L., Li X., Zhang G., Guo J., Zhao D., et al. Endoribonuclease activities of porcine reproductive and respiratory syndrome virus nsp11 was essential for nsp11 to inhibit IFN-beta induction. Mol. Immunol. 2011, 48:1568-1572.
58. Knoops K., Kikkert M., Worm S.H., Zevenhoven-Dobbe J.C., van der Meer Y., Koster A.J., et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008, 6:e226.
59. de Wilde A.H., Raj V.S., Oudshoorn D., Bestebroer T.M., van Nieuwkoop S., Limpens R.W., et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J. Gen. Virol. 2013, 94:1749-1760.
60. Lu X., Pan J., Tao J., Guo D. SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes 2011, 42:37-45.
61. Kopecky-Bromberg S.A., Martinez-Sobrido L., Frieman M., Baric R.A., Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 2007, 81:548-557.
62. Freundt E.C., Yu L., Park E., Lenardo M.J., Xu X.N. Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein. J. Virol. 2009, 83:6631-6640.
63. Siu K.L., Kok K.H., Ng M.H., Poon V.K., Yuen K.Y., Zheng B.J., et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J. Biol. Chem. 2009, 284:16202-16209.
64. Chen X., Yang X., Zheng Y., Yang Y., Xing Y., Chen Z. SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex. Protein Cell. 2014, 5:369-381.
65. Sun L., Xing Y., Chen X., Zheng Y., Yang Y., Nichols D.B., et al. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One 2012, 7:e30802.
66. Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. 2009, 83:6689-6705.
67. Zinzula L., Tramontano E. Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit. Antiviral Res. 2013, 100:615-635.
68. Maringer K., Fernandez-Sesma A. Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection. Cytokine Growth Factor Rev. 2014.
69. Kok K.H., Lui P.Y., Ng M.H., Siu K.L., Au S.W., Jin D.Y. The double-stranded RNA-binding protein PACT functions as a cellular activator of RIG-I to facilitate innate antiviral response. Cell Host Microbe. 2011, 9:299-309.
70. Siu K.L., Yeung M.L., Kok K.H., Yuen K.S., Kew C., Lui P.Y., et al. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J. Virol. 2014, 88:4866-4876.
71. Matthews K.L., Coleman C.M., van der Meer Y., Snijder E.J., Frieman M.B. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J. Gen. Virol. 2014, 95:874-882.
72. Bidet K., Garcia-Blanco M.A. Flaviviral RNAs: weapons and targets in the war between virus and host. Biochem. J. 2014, 462:215-230.
73. Ye J., Zhu B., Fu Z.F., Chen H., Cao S. Immune evasion strategies of flaviviruses. Vaccine 2013, 31:461-471.
74. Liu L., Dong H., Chen H., Zhang J., Ling H., Li Z., et al. Flavivirus RNA cap methyltransferase: structure, function, and inhibition. Front. Biol. (Beijing) 2010, 5:286-303.
75. Heinz F.X., Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012, 30:4301-4306.
76. Marston H.D., Folkers G.K., Morens D.M., Fauci A.S. Emerging viral diseases: confronting threats with new technologies. Sci. Transl. Med. 2014, 6:253ps210.
77. Morrison J., Aguirre S., Fernandez-Sesma A. Innate immunity evasion by dengue virus. Viruses 2012, 4:397-413.
78. Suthar M.S., Diamond M.S., Gale M. West Nile virus infection and immunity. Nat. Rev. Microbiol. 2013, 11:115-128.
79. Dong H., Zhang B., Shi P.Y. Flavivirus methyltransferase: a novel antiviral target. Antiviral Res. 2008, 80:1-10.
80. Szretter K.J., Daniels B.P., Cho H., Gainey M.D., Yokoyama W.M., Gale M., et al. 2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog. 2012, 8:e1002698.
81. Kimura T., Katoh H., Kayama H., Saiga H., Okuyama M., Okamoto T., et al. Ifit1 inhibits Japanese encephalitis virus replication through binding to 5' capped 2'-O unmethylated RNA. J. Virol. 2013, 87:9997-10003.
82. Gillespie L.K., Hoenen A., Morgan G., Mackenzie J.M. The endoplasmic reticulum provides the membrane platform for biogenesis of the flavivirus replication complex. J. Virol. 2010, 84:10438-10447.
83. Welsch S., Miller S., Romero-Brey I., Merz A., Bleck C.K., Walther P., et al. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe. 2009, 5:365-375.
84. Rodriguez-Madoz J.R., Bernal-Rubio D., Kaminski D., Boyd K., Fernandez-Sesma A. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J. Virol. 2010, 84:4845-4850.
85. Rodriguez-Madoz J.R., Belicha-Villanueva A., Bernal-Rubio D., Ashour J., Ayllon J., Fernandez-Sesma A. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J. Virol. 2010, 84:9760-9774.
86. Aguirre S., Maestre A.M., Pagni S., Patel J.R., Savage T., Gutman D., et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog. 2012, 8:e1002934.
87. Yu C.Y., Chang T.H., Liang J.J., Chiang R.L., Lee Y.L., Liao C.L., et al. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog. 2012, 8:e1002780.
88. Horner S.M. Activation and evasion of antiviral innate immunity by hepatitis C virus. J. Mol. Biol. 2014, 426:1198-1209.
89. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009, 29(Suppl. 1):74-81.
90. Metz P., Reuter A., Bender S., Bartenschlager R. Interferon-stimulated genes and their role in controlling hepatitis C virus. J. Hepatol. 2013, 59:1331-1341.
91. Morikawa K., Lange C.M., Gouttenoire J., Meylan E., Brass V., Penin F., et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J. Viral Hepat. 2011, 18:305-315.
92. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
93. Li X.D., Sun L., Seth R.B., Pineda G., Chen Z.J. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17717-17722.
94. Horner S.M., Liu H.M., Park H.S., Briley J., Gale M. Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14590-14595.
95. Lin R., Lacoste J., Nakhaei P., Sun Q., Yang L., Paz S., et al. Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage. J. Virol. 2006, 80:6072-6083.
96. Bellecave P., Sarasin-Filipowicz M., Donze O., Kennel A., Gouttenoire J., Meylan E., et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 2010, 51:1127-1136.
97. Nitta S., Sakamoto N., Nakagawa M., Kakinuma S., Mishima K., Kusano-Kitazume A., et al. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology 2013, 57:46-58.
98. Ding Q., Cao X., Lu J., Huang B., Liu Y.J., Kato N., et al. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J. Hepatol. 2013, 59:52-58.
99. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C., Ikeda M., et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2992-2997.
100. Chen Y., Chen J., Wang H., Shi J., Wu K., Liu S., et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog. 2013, 9:e1003248.
101. Abe T., Kaname Y., Hamamoto I., Tsuda Y., Wen X., Taguwa S., et al. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J. Virol. 2007, 81:8953-8966.
102. Sato K., Ishikawa T., Okumura A., Yamauchi T., Sato S., Ayada M., et al. Expression of Toll-like receptors in chronic hepatitis C virus infection. J. Gastroenterol. Hepatol. 2007, 22:1627-1632.
103. Motavaf M., Noorbakhsh F., Alavian S.M., Sharifi Z. Distinct toll-like receptor 3 and 7 expression in peripheral blood mononuclear cells from patients with chronic hepatitis C infection. Hepat. Mon. 2014, 14:e16421.
104. Yang Q., Fu S., Wang J. Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758. Arch. Virol. 2014, 159:2997-3003.
105. Takahashi K., Asabe S., Wieland S., Garaigorta U., Gastaminza P., Isogawa M., et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7431-7436.
106. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 2000, 20:17-35.
107. Dill M.T., Duong F.H., Vogt J.E., Bibert S., Bochud P.Y., Terracciano L., et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011, 140:1021-1031.
108. Chattergoon M.A., Latanich R., Quinn J., Winter M.E., Buckheit R.W., Blankson J.N., et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog. 2014, 10:e1004082.
109. Yue M., Feng L., Tang S.D., Wang J.J., Xue X.X., Ding W.L., et al. Sex-specific association between X-linked Toll-like receptor 7 with the outcomes of hepatitis C virus infection. Gene 2014, 548:244-250.
110. Arnaud N., Dabo S., Akazawa D., Fukasawa M., Shinkai-Ouchi F., Hugon J., et al. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 2011, 7:e1002289.
111. Eisele E., Siliciano R.F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012, 37:377-388.
112. Sgarbanti M., Battistini A. Therapeutics for HIV-1 reactivation from latency. Curr. Opin. Virol. 2013, 3:394-401.
113. Battistini A., Sgarbanti M. HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses 2014, 6:1715-1758.
114. Marsili G., Remoli A.L., Sgarbanti M., Perrotti E., Fragale A., Battistini A. HIV-1, interferon and the interferon regulatory factor system: an interplay between induction, antiviral responses and viral evasion. Cytokine Growth Factor Rev. 2012, 23:255-270.
115. Rustagi A., Gale M. Innate antiviral immune signaling, viral evasion and modulation by HIV-1. J. Mol. Biol. 2014, 426:1161-1177.
116. Iwasaki A. Innate immune recognition of HIV-1. Immunity 2012, 37:389-398.
117. Douville R.N., Hiscott J. The interface between the innate interferon response and expression of host retroviral restriction factors. Cytokine 2010, 52:108-115.
118. van Montfoort N., Olagnier D., Hiscott J. Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors. Cytokine Growth Factor Rev. 2014.
119. Acchioni C., Marsili G., Perrotti E., Remoli A.L., Sgarbanti M., Battistini A. Type I IFN - a blunt spear in fighting HIV-1 infection. Cytokine Growth Factor Rev. 2015, 26:143-158.
120. Towers G.J., Noursadeghi M. Interactions between HIV-1 and the cell-autonomous innate immune system. Cell Host Microbe. 2014, 16:10-18.
121. Luban J. Innate immune sensing of HIV-1 by dendritic cells. Cell Host Microbe. 2012, 12:408-418.
122. Ryoo J., Choi J., Oh C., Kim S., Seo M., Kim S.Y., et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat. Med. 2014, 20:936-941.
123. Sze A., Olagnier D., Lin R., van Grevenynghe J., Hiscott J. SAMHD1 host restriction factor: a link with innate immune sensing of retrovirus infection. J. Mol. Biol. 2013, 425:4981-4994.
124. Laguette N., Sobhian B., Casartelli N., Ringeard M., Chable-Bessia C., Segeral E., et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474:654-657.
125. Hrecka K., Hao C., Gierszewska M., Swanson S.K., Kesik-Brodacka M., Srivastava S., et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474:658-661.
126. Manches O., Frleta D., Bhardwaj N. Dendritic cells in progression and pathology of HIV infection. Trends Immunol. 2014, 35:114-122.
127. Gringhuis S.I., van der Vlist M., van den Berg L.M., den Dunnen J., Litjens M., Geijtenbeek T.B. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat. Immunol. 2010, 11:419-426.
128. Solis M., Nakhaei P., Jalalirad M., Lacoste J., Douville R., Arguello M., et al. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J. Virol. 2011, 85:1224-1236.
129. Jakobsen M.R., Bak R.O., Andersen A., Berg R.K., Jensen S.B., Tengchuan J., et al. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E4571-E4580.
130. Yan N., Regalado-Magdos A.D., Stiggelbout B., Lee-Kirsch M.A., Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 2010, 11:1005-1013.
131. Doitsh G., Galloway N.L., Geng X., Yang Z., Monroe K.M., Zepeda O., et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014, 505:509-514.
132. Lahaye X., Satoh T., Gentili M., Cerboni S., Conrad C., Hurbain I., et al. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity 2013, 39:1132-1142.
133. Rasaiyaah J., Tan C.P., Fletcher A.J., Price A.J., Blondeau C., Hilditch L., et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 2013, 503:402-405.
134. Chowell G., Nishiura H. Transmission dynamics and control of Ebola virus disease (EVD): a review. BMC Med. 2014, 12:196.
135. Wong G., Kobinger G.P., Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev. Clin. Immunol. 2014, 10:781-790.
136. Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 2001, 82:1365-1373.
137. Basler C.F., Amarasinghe G.K. Evasion of interferon responses by Ebola and Marburg viruses. J. Interferon Cytokine Res. 2009, 29:511-520.
138. Ramanan P., Shabman R.S., Brown C.S., Amarasinghe G.K., Basler C.F., Leung D.W. Filoviral immune evasion mechanisms. Viruses 2011, 3:1634-1649.
139. Bale S., Julien J.P., Bornholdt Z.A., Kimberlin C.R., Halfmann P., Zandonatti M.A., et al. Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog. 2012, 8:e1002916.
140. Ramanan P., Edwards M.R., Shabman R.S., Leung D.W., Endlich-Frazier A.C., Borek D.M., et al. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20661-20666.
141. Decker T., Muller M., Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 2005, 5:675-687.
142. Matsuura M. Structural modifications of bacterial lipopolysaccharide that facilitate gram-negative bacteria evasion of host innate immunity. Front. Immunol. 2013, 4:109.
143. Paciello I., Silipo A., Lembo-Fazio L., Curcuru L., Zumsteg A., Noel G., et al. Intracellular Shigella remodels its LPS to dampen the innate immune recognition and evade inflammasome activation. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E4345-E4354.
144. Sweet C.R., Conlon J., Golenbock D.T., Goguen J., Silverman N. YopJ targets TRAF proteins to inhibit TLR-mediated NF-kappaB, MAPK and IRF3 signal transduction. Cell. Microbiol. 2007, 9:2700-2715.
145. Sanada T., Kim M., Mimuro H., Suzuki M., Ogawa M., Oyama A., et al. The Shigella flexneri effector OspI deamidates UBC13 to dampen the inflammatory response. Nature 2012, 483:623-626.
146. Yan D., Wang X., Luo L., Cao X., Ge B. Inhibition of TLR signaling by a bacterial protein containing immunoreceptor tyrosine-based inhibitory motifs. Nat. Immunol. 2012, 13:1063-1071.
147. Sharma S., tenOever B.R., Grandvaux N., Zhou G.P., Lin R., Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003, 300:1148-1151.
148. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 2003, 4:491-496.
149. Savitsky D., Tamura T., Yanai H., Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol. Immunother. 2010, 59:489-510.
150. Battistini A. Interferon Regulatory Factors in Immune Cell Development and Host Response to Infection 2012, Nova Science Publishers, Inc.
151. Negishi H., Fujita Y., Yanai H., Sakaguchi S., Ouyang X., Shinohara M., et al. Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:15136-15141.
152. Dixit E., Boulant S., Zhang Y., Lee A.S., Odendall C., Shum B., et al. Peroxisomes are signaling platforms for antiviral innate immunity. Cell 2010, 141:668-681.
153. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
154. Devaraj S.G., Wang N., Chen Z., Chen Z., Tseng M., Barretto N., et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 2007, 282:32208-32221.
155. Yang X., Chen X., Bian G., Tu J., Xing Y., Wang Y., et al. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J. Gen. Virol. 2014, 95:614-626.
156. Liu Y.C., Penninger J., Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat. Rev. Immunol. 2005, 5:941-952.
157. Wilson J.R., de Sessions P.F., Leon M.A., Scholle F. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J. Virol. 2008, 82:8262-8271.
158. Morrison C.R., Scholle F. Abrogation of TLR3 inhibition by discrete amino acid changes in the C-terminal half of the West Nile virus NS1 protein. Virology 2014, 456-457:96-107.
159. Crook K.R., Miller-Kittrell M., Morrison C.R., Scholle F. Modulation of innate immune signaling by the secreted form of the West Nile virus NS1 glycoprotein. Virology 2014, 458-459:172-182.
160. Anglero-Rodriguez Y.I., Pantoja P., Sariol C.A. Dengue virus subverts the interferon induction pathway via NS2B/3 protease-IkappaB kinase epsilon interaction. Clin. Vaccine Immunol. 2014, 21:29-38.
161. Robertson S.J., Lubick K.J., Freedman B.A., Carmody A.B., Best S.M. Tick-borne flaviviruses antagonize both IRF-1 and type I IFN signaling to inhibit dendritic cell function. J. Immunol. 2014, 192:2744-2755.
162. Otsuka M., Kato N., Moriyama M., Taniguchi H., Wang Y., Dharel N., et al. Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. Hepatology 2005, 41:1004-1012.
163. Kaukinen P., Sillanpaa M., Nousiainen L., Melen K., Julkunen I. Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKepsilon and TBK1 functions. J. Med. Virol. 2013, 85:71-82.
164. Inoue K., Tsukiyama-Kohara K., Matsuda C., Yoneyama M., Fujita T., Kuge S., et al. Impairment of interferon regulatory factor-3 activation by hepatitis C virus core protein basic amino acid region 1. Biochem. Biophys. Res. Commun. 2012, 428:494-499.
165. Oshiumi H., Sakai K., Matsumoto M., Seya T. DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-beta-inducing potential. Eur. J. Immunol. 2010, 40:940-948.
166. Oshiumi H., Ikeda M., Matsumoto M., Watanabe A., Takeuchi O., Akira S., et al. Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction. PLoS One 2010, 5:e14258.
167. Ciccaglione A.R., Stellacci E., Marcantonio C., Muto V., Equestre M., Marsili G., et al. Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J. Virol. 2007, 81:202-214.
168. Stone A.E., Mitchell A., Brownell J., Miklin D.J., Golden-Mason L., Polyak S.J., et al. Hepatitis C virus core protein inhibits interferon production by a human plasmacytoid dendritic cell line and dysregulates interferon regulatory factor-7 and signal transducer and activator of transcription (STAT) 1 protein expression. PLoS One 2014, 9:e95627.
169. Remoli A.L., Marsili G., Sgarbanti M., Perrotti E., Fragale A., Orsatti R., Battistini A. HIV-1 targeting of IFN regulatory factors. Fut. Virol. 2011, 6:1397-1405.
170. Doehle B.P., Hladik F., McNevin J.P., McElrath M.J., Gale M. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J. Virol. 2009, 83:10395-10405.
171. Okumura A., Alce T., Lubyova B., Ezelle H., Strebel K., Pitha P.M. HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 2008, 373:85-97.
172. Doehle B.P., Chang K., Fleming L., McNevin J., Hladik F., McElrath M.J., et al. Vpu-deficient HIV strains stimulate innate immune signaling responses in target cells. J. Virol. 2012, 86:8499-8506.
173. Park S.Y., Waheed A.A., Zhang Z.R., Freed E.O., Bonifacino J.S. HIV-1 Vpu induces caspase-mediated cleavage of IRF3. J. Biol. Chem. 2014.
174. Gougeon M.L. Apoptosis as an HIV strategy to escape immune attack. Nat. Rev. Immunol. 2003, 3:392-404.
175. Harman A.N., Lai J., Turville S., Samarajiwa S., Gray L., Marsden V., et al. HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood 2011, 118:298-308.
176. Sgarbanti M., Remoli A.L., Marsili G., Ridolfi B., Borsetti A., Perrotti E., et al. IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. J. Virol. 2008, 82:3632-3641.
177. Sgarbanti M., Borsetti A., Moscufo N., Bellocchi M.C., Ridolfi B., Nappi F., et al. Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J. Exp. Med. 2002, 195:1359-1370.
178. Remoli A.L., Marsili G., Perrotti E., Gallerani E., Ilari R., Nappi F., et al. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem. J. 2006, 396:371-380.
179. Sgarbanti M., Marsili G., Remoli A.L., Stellacci E., Mai A., Rotili D., et al. IkappaB kinase epsilon targets interferon regulatory factor 1 in activated T lymphocytes. Mol. Cell. Biol. 2014, 34:1054-1065.
180. Basler C.F., Mikulasova A., Martinez-Sobrido L., Paragas J., Muhlberger E., Bray M., et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003, 77:7945-7956.
181. Prins K.C., Cardenas W.B., Basler C.F. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 2009, 83:3069-3077.
182. Prins K.C., Binning J.M., Shabman R.S., Leung D.W., Amarasinghe G.K., Basler C.F. Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J. Virol. 2010, 84:10581-10591.
183. Chang T.H., Kubota T., Matsuoka M., Jones S., Bradfute S.B., Bray M., et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 2009, 5:e1000493.
184. Kubota T., Matsuoka M., Chang T.H., Tailor P., Sasaki T., Tashiro M., et al. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J. Biol. Chem. 2008, 283:25660-25670.
185. Negishi H., Matsuki K., Endo N., Sarashina H., Miki S., Matsuda A., et al. Beneficial innate signaling interference for antibacterial responses by a Toll-like receptor-mediated enhancement of the MKP-IRF3 axis. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:19884-19889.
186. Minakshi R., Padhan K., Rani M., Khan N., Ahmad F., Jameel S. The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS One 2009, 4:e8342.
187. Li S.W., Lai C.C., Ping J.F., Tsai F.J., Wan L., Lin Y.J., et al. Severe acute respiratory syndrome coronavirus papain-like protease suppressed alpha interferon-induced responses through downregulation of extracellular signal-regulated kinase 1-mediated signalling pathways. J. Gen. Virol. 2011, 92:1127-1140.
188. Frieman M., Yount B., Heise M., Kopecky-Bromberg S.A., Palese P., Baric R.S. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J. Virol. 2007, 81:9812-9824.
189. Liu J., HuangFu W.C., Kumar K.G., Qian J., Casey J.P., Hamanaka R.B., et al. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe. 2009, 5:72-83.
190. Ambrose R.L., Mackenzie J.M. A conserved peptide in West Nile virus NS4A protein contributes to proteolytic processing and is essential for replication. J. Virol. 2011, 85:11274-11282.
191. Best S.M., Morris K.L., Shannon J.G., Robertson S.J., Mitzel D.N., Park G.S., et al. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J. Virol. 2005, 79:12828-12839.
192. Park G.S., Morris K.L., Hallett R.G., Bloom M.E., Best S.M. Identification of residues critical for the interferon antagonist function of Langat virus NS5 reveals a role for the RNA-dependent RNA polymerase domain. J. Virol. 2007, 81:6936-6946.
193. Munoz-Jordan J.L., Laurent-Rolle M., Ashour J., Martinez-Sobrido L., Ashok M., Lipkin W.I., et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 2005, 79:8004-8013.
194. Mazzon M., Jones M., Davidson A., Chain B., Jacobs M. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J. Infect. Dis. 2009, 200:1261-1270.
195. Ashour J., Laurent-Rolle M., Shi P.Y., Garcia-Sastre A. NS5 of dengue virus mediates STAT2 binding and degradation. J. Virol. 2009, 83:5408-5418.
196. Morrison J., Laurent-Rolle M., Maestre A.M., Rajsbaum R., Pisanelli G., Simon V., et al. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog. 2013, 9:e1003265.
197. Lin R.J., Chang B.L., Yu H.P., Liao C.L., Lin Y.L. Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism. J. Virol. 2006, 80:5908-5918.
198. Werme K., Wigerius M., Johansson M. Tick-borne encephalitis virus NS5 associates with membrane protein scribble and impairs interferon-stimulated JAK-STAT signalling. Cell. Microbiol. 2008, 10:696-712.
199. Zhang Q., Gong R., Qu J., Zhou Y., Liu W., Chen M., et al. Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway. J. Virol. 2012, 86:1544-1554.
200. Heim M.H., Moradpour D., Blum H.E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J. Virol. 1999, 73:8469-8475.
201. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003, 17:488-490.
202. Luquin E., Larrea E., Civeira M.P., Prieto J., Aldabe R. HCV structural proteins interfere with interferon-alpha Jak/STAT signalling pathway. Antiviral Res. 2007, 76:194-197.
203. Keskinen P., Melen K., Julkunen I. Expression of HCV structural proteins impairs IFN-mediated antiviral response. Virology 2002, 299:164-171.
204. Xu J., Liu S., Xu Y., Tien P., Gao G. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha. Virus Res. 2009, 141:55-62.
205. Duong F.H., Filipowicz M., Tripodi M., La Monica N., Heim M.H. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004, 126:263-277.
206. Horner S.M., Gale M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J. Interferon Cytokine Res. 2009, 29:489-498.
207. Lan K.H., Lan K.L., Lee W.P., Sheu M.L., Chen M.Y., Lee Y.L., et al. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J. Hepatol. 2007, 46:759-767.
208. Reid S.P., Valmas C., Martinez O., Sanchez F.M., Basler C.F. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 2007, 81:13469-13477.
209. Mateo M., Reid S.P., Leung L.W., Basler C.F., Volchkov V.E. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J. Virol. 2010, 84:1169-1175.
210. Xu W., Edwards M.R., Borek D.M., Feagins A.R., Mittal A., Alinger J.B., et al. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe. 2014, 16:187-200.
211. Zhang A.P., Bornholdt Z.A., Liu T., Abelson D.M., Lee D.E., Li S., et al. The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog. 2012, 8:e1002550.
212. Valmas C., Grosch M.N., Schumann M., Olejnik J., Martinez O., Best S.M., et al. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog. 2010, 6:e1000721.
213. Warnking K., Klemm C., Loffler B., Niemann S., van Kruchten A., Peters G., et al. Super-infection with Staphylococcus aureus inhibits influenza virus-induced type I IFN signaling through impaired STAT1-STAT2 dimerization. Cell. Microbiol. 2014.
214. Prabhakar S., Qiao Y., Hoshino Y., Weiden M., Canova A., Giacomini E., et al. Inhibition of response to alpha interferon by Mycobacterium tuberculosis. Infect. Immun. 2003, 71:2487-2497.
215. Miettinen M., Lehtonen A., Julkunen I., Matikainen S. Lactobacilli and Streptococci activate NF-kappa B and STAT signaling pathways in human macrophages. J. Immunol. 2000, 164:3733-3740.
216. Schoggins J.W. Interferon-stimulated genes: roles in viral pathogenesis. Curr. Opin. Virol. 2014, 6:40-46.
217. Zheng Y.H., Jeang K.T., Tokunaga K. Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology 2012, 9:112.
218. Yan N., Chen Z.J. Intrinsic antiviral immunity. Nat. Immunol. 2012, 13:214-222.
219. Duggal N.K., Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat. Rev. Immunol. 2012, 12:687-695.
220. Pfaller C.K., Li Z., George C.X., Samuel C.E. Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old players as modulators of the interferon response. Curr. Opin. Immunol. 2011, 23:573-582.
221. Garcia M.A., Meurs E.F., Esteban M. The dsRNA protein kinase PKR: virus and cell control. Biochimie 2007, 89:799-811.
222. Langland J.O., Cameron J.M., Heck M.C., Jancovich J.K., Jacobs B.L. Inhibition of PKR by RNA and DNA viruses. Virus Res. 2006, 119:100-110.
223. Dauber B., Wolff T. Activation of the antiviral kinase PKR and viral countermeasures. Viruses 2009, 1:523-544.
224. Arnaud N., Dabo S., Maillard P., Budkowska A., Kalliampakou K.I., Mavromara P., et al. Hepatitis C virus controls interferon production through PKR activation. PLoS One 2010, 5:e10575.
225. Toroney R., Nallagatla S.R., Boyer J.A., Cameron C.E., Bevilacqua P.C. Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A. J. Mol. Biol. 2010, 400:393-412.
226. Garaigorta U., Chisari F.V. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe. 2009, 6:513-522.
227. Thimme R., Binder M., Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol. Rev. 2012, 36:663-683.
228. Tu Y.C., Yu C.Y., Liang J.J., Lin E., Liao C.L., Lin Y.L. Blocking double-stranded RNA-activated protein kinase PKR by Japanese encephalitis virus nonstructural protein 2A. J. Virol. 2012, 86:10347-10358.
229. Schumann M., Gantke T., Muhlberger E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 2009, 83:8993-8997.
230. Feng Z., Cerveny M., Yan Z., He B. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J. Virol. 2007, 81:182-192.
231. Cardenas W.B., Loo Y.M., Gale M., Hartman A.L., Kimberlin C.R., Martinez-Sobrido L., et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 2006, 80:5168-5178.
232. Luthra P., Ramanan P., Mire C.E., Weisend C., Tsuda Y., Yen B., et al. Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe. 2013, 14:74-84.
233. Clerzius G., Gelinas J.F., Gatignol A. Multiple levels of PKR inhibition during HIV-1 replication. Rev. Med. Virol. 2011, 21:42-53.
234. Clerzius G., Shaw E., Daher A., Burugu S., Gelinas J.F., Ear T., et al. The PKR activator, PACT, becomes a PKR inhibitor during HIV-1 replication. Retrovirology 2013, 10:96.
235. Burugu S., Daher A., Meurs E.F., Gatignol A. HIV-1 translation and its regulation by cellular factors PKR and PACT. Virus Res. 2014.
236. Morales D.J., Lenschow D.J. The antiviral activities of ISG15. J. Mol. Biol. 2013, 425:4995-5008.
237. Zhao C., Collins M.N., Hsiang T.Y., Krug R.M. Interferon-induced ISG15 pathway: an ongoing virus-host battle. Trends Microbiol. 2013, 21:181-186.
238. Shi H.X., Yang K., Liu X., Liu X.Y., Wei B., Shan Y.F., et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol. Cell. Biol. 2010, 30:2424-2436.
239. Durfee L.A., Lyon N., Seo K., Huibregtse J.M. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol. Cell 2010, 38:722-732.
240. Okumura A., Pitha P.M., Harty R.N. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3974-3979.
241. Okumura A., Lu G., Pitha-Rowe I., Pitha P.M. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1440-1445.
242. Lindner H.A., Fotouhi-Ardakani N., Lytvyn V., Lachance P., Sulea T., Menard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J. Virol. 2005, 79:15199-15208.
243. Clementz M.A., Chen Z., Banach B.S., Wang Y., Sun L., Ratia K., et al. Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J. Virol. 2010, 84:4619-4629.
244. Ratia K., Kilianski A., Baez-Santos Y.M., Baker S.C., Mesecar A. Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease. PLoS Pathog. 2014, 10:e1004113.
245. Kim M.J., Yoo J.Y. Inhibition of hepatitis C virus replication by IFN-mediated ISGylation of HCV-NS5A. J. Immunol. 2010, 185:4311-4318.
246. Broering R., Zhang X., Kottilil S., Trippler M., Jiang M., Lu M., et al. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut 2010, 59:1111-1119.
247. Chen L., Sun J., Meng L., Heathcote J., Edwards A.M., McGilvray I.D. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J. Gen. Virol. 2010, 91:382-388.
248. Zhang X., Bogunovic D., Payelle-Brogard B., Francois-Newton V., Speer S.D., Yuan C., et al. Human intracellular ISG15 prevents interferon-alpha/beta over-amplification and auto-inflammation. Nature 2014.
249. Li Y., Li S., Duan X., Liu B., Yang C., Zeng P., et al. Activation of endogenous type I IFN signaling contributes to persistent HCV infection. Rev. Med. Virol. 2014, 24:332-342.
250. Dauphinee S.M., Richer E., Eva M.M., McIntosh F., Paquet M., Dangoor D., et al. Contribution of increased ISG15, ISGylation and deregulated type I IFN signaling in Usp18 mutant mice during the course of bacterial infections. Genes Immun. 2014, 15:282-292.
251. Dorhoi A., Yeremeev V., Nouailles G., Weiner J., Jorg S., Heinemann E., et al. Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur. J. Immunol. 2014, 44:2380-2393.
252. Ottenhoff T.H., Dass R.H., Yang N., Zhang M.M., Wong H.E., Sahiratmadja E., et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PloS One 2012, 7:e45839.
253. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
254. Maertzdorf J., Weiner J., Mollenkopf H.J., Bauer T., Prasse A., Muller-Quernheim J., et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:7853-7858.
255. Chakravortty D., Hensel M. Inducible nitric oxide synthase and control of intracellular bacterial pathogens. Microbes Infect. 2003, 5:621-627.
256. Panday A., Sahoo M.K., Osorio D., Batra S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell. Mol. Immunol. 2014.
257. Vazquez-Torres A., Xu Y., Jones-Carson J., Holden D.W., Lucia S.M., Dinauer M.C., et al. Salmonella pathogenicity island 2-dependent evasion of the phagocyte NADPH oxidase. Science 2000, 287:1655-1658.
258. Vallance B.A., Deng W., De Grado M., Chan C., Jacobson K., Finlay B.B. Modulation of inducible nitric oxide synthase expression by the attaching and effacing bacterial pathogen Citrobacter rodentium in infected mice. Infect. Immun. 2002, 70:6424-6435.
259. Zust R., Dong H., Li X.F., Chang D.C., Zhang B., Balakrishnan T., et al. Rational design of a live attenuated dengue vaccine: 2'-O-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog. 2013, 9:e1003521.
260. Malireddi R.K., Kanneganti T.D. Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection. Front. Cell. Infect. Microbiol. 2013, 3:77.